Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
about
Genomic diversity of colorectal cancer: Changing landscape and emerging targetsBRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesCombined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.Colorectal clinical trials: what is on the horizon?Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.Recent developments in the treatment of metastatic colorectal cancer.Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma.Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience.BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?
P2860
Q26739052-5D55FDFF-7DE4-440A-A8C1-EC8D944E9A9DQ26772276-F7F81BBC-4FEF-4A67-A6A8-ED3B76EB1A41Q27853216-FFCA7281-EE38-45B8-8216-3DAE8DD7EE11Q27853224-98C991A3-EDAC-4BF5-A617-C444C2398939Q37157958-8B357498-EFD1-4D41-9995-619FA439D8ABQ37408262-C4E8810F-BFCD-44CF-9323-34AD65704EEFQ38730744-5CF2E87C-D5EC-443C-A1A9-6ACF1E1CD1B7Q40428222-3F67A31B-F8AC-4012-B629-67826D91E954Q41105389-0967198D-E7FC-467F-A49F-575A70B2EB95Q43138932-28D32140-6D18-40EE-A194-11CF98683B4CQ44846764-98A336DF-2505-4C9F-8F36-04258B51B0B6Q47640854-C18A7D55-AFB5-4FB8-AAC7-CA5E703A9835Q47767987-F6F5AC5C-AB3B-4A0B-8593-13C0A85BB7C9Q50066241-8E791A6F-A2C6-4167-AE42-62A960A0DB2AQ50897558-9C378CB8-63F4-45D0-BEB9-E3D0CBE7BD23
P2860
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@ast
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@en
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@nl
type
label
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@ast
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@en
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@nl
prefLabel
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@ast
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@en
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@nl
P2093
P2860
P1476
Progression-free survival rema ...... BRAF-mutated colorectal cancer
@en
P2093
Arvind Dasari
Christopher Garrett
David Fogelman
Dipen Maru
Michael J Overman
Robert Wolff
Shweta Agarwal
Van Morris
P2860
P304
P356
10.1016/J.CLCC.2014.06.001
P407
P50
P577
2014-06-23T00:00:00Z